Reported July 30: Annexon Inks $200M Credit Facility Agreement With Oxford Finance
Citizens Initiates Coverage On Annexon with Market Underperform Rating, Announces Price Target of $3
Needham Maintains Buy on Annexon, Raises Price Target to $25
Annexon Presents Data On Neuroprotective Effect Of Vonaprument At American Society Of Retina Specialists 44th Annual Scientific Meeting
Annexon: Perfect Complement To A Speculative Biotech Portfolio
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Annexon Eyes ‘Win Season’ With Q4 Vision Trial Data, GBS Filings Ahead
Annexon, Inc. (ANNX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Annexon Maps 3 Big Pipeline Catalysts Ahead of Q4 Vision-Drug Readout
Annexon to Participate in Upcoming June Investor Conferences
Annexon Highlights Q4 Geographic Atrophy Data, GBS Filing Plans at BofA Conference
Annexon, Inc. (ANNX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Goldman Sachs Initiates Coverage On Annexon with Neutral Rating, Announces Price Target of $7
Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones
Annexon Q1 EPS $(0.23) Beats $(0.29) Estimate
Annexon to Present at the Bank of America Securities Health Care Conference 2026
Annexon (ANNX): 7 Small Cap Stocks with the Highest Upside Potential
Annexon Biosciences (ANNX) Buy Rating Retained
Annexon CEO Touts “Win Year” 2026 at Needham, Eyes GA Phase III Data and GBS FDA Filing
Annexon to Present at the 25th Annual Needham Virtual Healthcare Conference
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.